Eli Lilly Boehringer Ingelheim launch Abasaglar biosimilar against Sanofi's Lantus | Network with Boehringer Ingelheim and Sanofi at Biosimilars and Biobetters

SMi's 6th annual Biosimilars and Biobetters conference, taking place on 30th September - 1st October 2015 in London, will cover regulatory updates, pharmacovigilance of biosimilars, patent litigation, market access, product commercialization barriers and global market developments. End Quote

(1888PressRelease) August 28, 2015 - Sanofi is facing further competition to its big-selling insulin drug Lantus in the UK, with Eli Lilly and Boehringer Ingelheim launching a biosimilar version this week. Lantus (insulin glargine) is the top-selling basal insulin in the world but competition from biosimilars and newer brands has started to eat into sales, which fell more than 5% to €3.3bn in the first six months of the year. Lilly and Boehringer's biosimilar was approved in Europe last September and introduced in some Eastern Europe markets earlier this year - including the Czech Republic, Slovakia and Estonia where pricing has also been set at around a 15%-20% discount to Sanofi's brand. However, the UK launch of Abasaglar - which follows its approval last September - marks the first competition to Lantus in a major EU pharma market. (Source: PMLive, "Lilly and Boehringer launch Lantus biosimilar in UK", 26th August 2015)

Against this backdrop, Boehringer Ingelheim and Sanofi have confirmed their attendance at SMi's 6th annual Biosimilars and Biobetters conference, taking place on the 30th September - 1st October 2015 in London. The two-day conference will provide the ideal platform to engage in scientific discussions and debate the best practices and solutions to improve industry performance through technical case studies and practical advice from leading biosimilar and regulatory players from organisations including Harvest Moon Pharmaceuticals USA Inc, GfK, Selecta Biosciences, Cinfa Biotech GmbH, Norwegian Medicines Agency and more.

Unique perspectives will be shared on:
• Evolving biosimilar regulatory landscape
• Market access and product commercialisation barriers
• How advanced structural characterisation techniques can support regulatory approval
• How to engage payers and clinicians on safety and adoption of biosimilars and biobetters

Speaker Panel includes:
• Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
• Shahin Kauser, Senior Scientific Assessor, MHRA
• Chris Teale, Vice President Europe, GfK NOP Ltd
• Bracha Timan, Director, Israel Site Head, Global Bioassays & Technology, Global R&D, Teva
• Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
• Karsten Roth, Director Clinical Operations, Cinfa Biotech GmbH
• Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Health
• Steinar Madsen, Medical Director, Norwegian Medicines Agency

To view the complete speaker line-up and two-day conference programme, visit http://www.biosimilars-biobetters.co.uk/1888pressrelease

###

space

Other Related Press Releases